Just got my poster set up at #SITC2025 and walking my first visitor through our data. If you’re here, stop by poster 919 to learn about the unique biology of TLR7/8/9!

Delighted that Luke Timmerman invited me on his Long Run podcast to tell Zola's story. It's been a long run for me, from discovering CpG DNA (TLR9) 30 yrs ago, to now discovering RNA/DNA TLR7/8/9 agonists, which may transform cancer immunotherapy!
timmermanreport.com/2025/10/inna...

Join us for the 3rd Nature Conference on Nucleic Acid Medicines in Boston (Dec 8-10) with an amazing lineup of speakers. 4 weeks left 4 early bird registration! natureconferences.streamgo.live/cracking-the...
@natureportfolio.nature.com @nature.com @natbiotech.nature.com @natrevdrugdiscov.nature.com

My new review article covers key points I have not seen in any other review of cancer immunotherapy: i) the difference between IFN-a and IFN-b; ii) the unique role of P1 pDC among all DC subsets; iii) the unique role of TLR7/8/9 among TLRs
nam10.safelinks.protection.outlook.com?url=http%3A%...

If you are an academic innovator interested in learning more about translating your research to real-world impact, apply to be a Termeer Scholar! Get your application in by Friday, August 29th at Midnight EST to be considered for this incredible opportunity!
www.linkedin.com/posts/termee...

I recently had the pleasure of joining
The Pharmaverse podcast - it released today. We discussed the parallels between running marathons (and ultras) and my >30 yrs of efforts activating immunity to fight cancer, culminating in founding Zola Rx, starting a biotech is harder! youtu.be/FX9MLqv9PBQ

Like most immunologists, I tend to use a lot of jargon when talking about cancer immunotherapy - so complex! A patient in one of our prior clinical trials asked me to explain our new approach with TLR7/8/9 agonists, and I made this video on the history, which he liked. youtu.be/KLgCU5Gm3pA

Thank you Brad Loncar for hosting us on Biotech TV - Jim and I appreciated the chance to explain how a deeper understanding of type one IFNs can propel cancer immunotherapy forward to greater success! RNA/DNA hybrids costimulate TLR7/8/9, inducing a novel IFN-a response without inflammation!

Can Cambridge biotech evolve with the times? I’m an optimist, but the challenges we face are clear and growing…

Tickets are SOLD OUT for the TR10 East Coast anniversary party Mar. 6 in Cambridge, Mass. Tickets still available for TR10 West Coast party Mar. 13. Register here. www.eventbrite.com/e/tr10-west-...

Cold day going up Mount Washington today with Doug Fambrough, Dave Melville, Jim Ellis, and friends! On the way up, Doug agreed to join me on the board of my new company, Zola therapeutics, getting work done while having fun!

A drug comprising 8 defined live bacterial strains reduces C diff. by >80%, cool!

I joined 75+ @nobelprize.bsky.social laureates urging US Senators to oppose RFK Jr.'s confirmation as DHHS Secretary. If you’re in a state with GOP senators, PLEASE reach out to them! I’d deeply appreciate it if you amplified this post! 🙏
www.nytimes.com/2024/12/09/h...

Mount Lafayette and Franconia Ridge are completely different in the winter, my favorite time of year to be up here!#AnotherGreatDayInTheMountains

It’s another great day to be in the mountains! Heading up the Old Bridle Path in Franconia notch…

It’s full on winter on Mount Washington, but the Lake of the Clouds hut still provides a nice wind break for hot coffee and a snack. Excellent conditions snowshoeing up ammo. Just past the hut, the trail disappears under deep drifts and there’s no visibility with blowing snow. Back down ammo!

Sunset right now in the blue Hills, the rocks are still a bit wet from the recent rain, so I’m taking it easy, enjoying the views!

For my inaugural post, I’m sharing this recent talk on the immune considerations in mRNA therapeutics. Optimizing CD8+ T cell responses requires understanding the biology of IFN-a/b, which has been ignored in recent cancer immunotherapy review articles.

youtu.be/Isz5FqRpqbM